Plain-English translation of NCT06741995 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers believe that certain antibodies in the blood — called anti-β1AR and anti-L-CaC antibodies — may help predict which patients with dilated cardiomyopathy will have serious complications or poor outcomes. This study will collect blood samples from 1,000 patients and follow them for 3 years to see if these blood markers are truly useful for predicting prognosis and guiding treatment decisions.
Dilated cardiomyopathy is a serious condition where the heart weakens and enlarges, but doctors don't yet have reliable ways to predict which patients will do worse. Previous smaller studies suggest these antibodies matter, but larger, more rigorous research across multiple hospitals is needed to confirm whether testing for them would actually help doctors care for patients better.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn to test for these specific antibodies, and then researchers will follow your health over 3 years—likely through periodic clinic visits and medical record reviews. There is no medication to take as part of this study; the focus is on understanding what your blood markers tell us about your heart condition and how you may do over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China